BioVie Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
-
51.00
229.40
229.40
Gross Income
-
-
51.00
229.40
229.40
SG&A Expense
322.40
233.40
381.00
1,324.20
2,142.80
EBIT
322.40
233.40
432.00
1,553.60
2,372.20
Non Operating Income/Expense
-
-
-
222.90
-
Interest Expense
-
-
0.10
-
41
Pretax Income
321.90
233.00
431.90
1,330.70
2,413.10
Consolidated Net Income
321.90
233.00
431.90
1,330.70
2,413.10
Net Income
321.90
233.00
431.90
1,330.70
2,413.10
Net Income After Extraordinaries
321.90
233.00
431.90
1,330.70
2,413.10
Net Income Available to Common
321.90
233.00
431.90
1,330.70
2,434.10
EPS (Basic)
0.00
0.00
0.00
0.01
0.03
Basic Shares Outstanding
87,083.60
87,210.00
87,198.90
89,391.30
95,758.10
EPS (Diluted)
0.00
0.00
0.00
0.01
0.03
Diluted Shares Outstanding
87,083.60
87,210.00
87,198.90
89,391.30
95,758.10
EBITDA
322.40
233.40
381.00
1,324.20
2,142.80
Non-Operating Interest Income
0.50
0.40
0.20
0.00
-

About BioVie

View Profile
Address
2120 Colorado Avenue
Santa Monica California 90404
United States
Employees -
Website http://www.biovieinc.com
Updated 07/08/2019
BioVie, Inc. is a development stage biotechnology company. The company engages in the discovery, development and commercialization of antibiotics for gram-negative and gram-positive bacterial infections. BioVie was founded on April 10, 2013 and is headquartered in Beverly, MA.